» Articles » PMID: 38945

Biochemical Discrimination of Hurler and Scheie Syndromes

Overview
Journal Clin Sci (Lond)
Date 1979 Sep 1
PMID 38945
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

1. Homogenates of cultured skin fibroblasts derived from patients with alpha-L-iduronidase-deficiency disorders (Hurler and Scheie syndromes) were capable of hydrolysing iduronosyl anhydro-[1-3H]mannitol 6-sulphate although at considerably reduced rates compared with normal controls. 2. The Vmax. values of alpha-L-iduronidase from patients with Hurler or Scheie syndromes and from normal controls were 11, 12 and 833 pmol min-1 mg-1 of protein respectively; the corresponding apparent Km values were 656, 50 and 53 mumol/l respectively. The alpha-L-iduronidases from normal and Scheie fibroblast homogenates were shown to exhibit pH optima at 3.6 and 4.1 and were competitively inhibited by both chloride and sulphate ions: Hurler alpha-L-iduronidase activity exhibited the pH optimum at 3.8 and was also inhibited by chloride and to a lesser extent by sulphate ions. 3. The thermal stability of Hurler, Scheie and normal alpha-L-iduronidase activities at 55 degrees C gave half-lives of approximately 1.0, 2.5 and 1.0 h respectively. 4. These biochemical findings clearly demonstrate enzyme differences for these two clinically distinct phenotypes and provide biochemical evidence that the Hurler and Scheie syndromes result from different allelic mutations.

Citing Articles

ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome.

Ou L, DeKelver R, Rohde M, Tom S, Radeke R, St Martin S Mol Ther. 2018; 27(1):178-187.

PMID: 30528089 PMC: 6319315. DOI: 10.1016/j.ymthe.2018.10.018.


Novel splice site IDUA gene mutation in Tunisian pedigrees with hurler syndrome.

Chkioua L, Boudabous H, Jaballi I, Grissa O, Ben Turkia H, Tebib N Diagn Pathol. 2018; 13(1):35.

PMID: 29843745 PMC: 5975427. DOI: 10.1186/s13000-018-0710-3.


Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.

Parenti G, Andria G, Valenzano K Mol Ther. 2015; 23(7):1138-1148.

PMID: 25881001 PMC: 4817787. DOI: 10.1038/mt.2015.62.


Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Valenzano K, Khanna R, Powe A, Boyd R, Lee G, Flanagan J Assay Drug Dev Technol. 2011; 9(3):213-35.

PMID: 21612550 PMC: 3102255. DOI: 10.1089/adt.2011.0370.


Review: the immunochemical analysis of enzyme from mucopolysaccharidoses patients.

Brooks D J Inherit Metab Dis. 1993; 16(1):3-15.

PMID: 8487500 DOI: 10.1007/BF00711309.